

10.May.2019



Consolidated Financial Results for FY2018

Consolidated Subsidiaries: 2

ASKA Pharmamedical Co., Ltd. / ASKA Animal Health Co., Ltd.

Consolidated	FY2017 Apr. 2017-Mar. 2018		FY2018 Apr. 2018-Mar. 2019		YoY
	Million Yen	Ratio	Million Yen	Ratio	
Net Sales	48,944	100.0%	46,706	100.0%	-4.6%
Cost of Sales	30,059	61.4%	27,814	59.6%	-7.5%
Gross Profit	18,884	38.6%	18,891	40.4%	0.0%
Selling, General and Administrative Expenses	16,060	32.8%	17,107	36.6%	6.5%
Operating Income	2,824	5.8%	1,782	3.8%	-36.9%
Profit Attributable to Owners of Parent	2,388	4.9%	1,744	3.7%	-27.0%

Financial Forecasts for FY2019

Consolidated	FY2018 Apr. 2018-Mar. 2019		FY2019 Apr. 2019-Mar. 2020		YoY
	Million Yen	Ratio	Million Yen	Ratio	
Net Sales	46,706	100.0%	53,000	100.0%	13.5%
Operating Income	1,782	3.8%	2,000	3.8%	12.2%
Profit Attributable to Owners of Parent	1,744	3.7%	1,000	1.9%	-42.7%

Trends in Main Product Sales

(Million Yen)

Therapeutic Category	Products	FY2017	FY2018	FY2019 Forecasts
Antihypertensive agents	CANDESARTAN※	13,226	11,920	13,600
Thyroid hormone	THYRADIN	4,912	5,660	6,980
LH-RH derivative	LEUPRORELIN	4,164	4,170	4,520
Poorly absorbable rifamycin antimicrobial agents	RIFXIMA	1,062	2,480	3,890
Hyperlipidemic agents	LIPDIL	4,292	1,800	1,210
Antihypertensive agents	AMLODIPINE	1,616	1,390	1,530
Emergency contraceptives	NORLEVO	1,208	1,290	660
Prostate cancer therapeutic agents	BICALUTAMIDE	1,576	1,220	1,060
Dysmenorrhea agents	FREWELL		670	2,010
GnRH antagonist	RELUMINA		360	1,980

※ Including CANDESARTAN formulation's sales